← Back to Clinical Trials
Recruiting Phase 2 NCT07435571

NCT07435571 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of Trapeziometacarpal Osteoarthritis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07435571
Status Recruiting
Phase Phase 2
Sponsor TBF Genie Tissulaire
Condition Trapeziometacarpal Osteoarthritis
Study Type INTERVENTIONAL
Enrollment 22 participants
Start Date 2026-11
Primary Completion 2028-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
with SclerFIX

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 22 participants in total. It began in 2026-11 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this clinical trial is to evaluate whether a human umbilical cord amniotic membrane allograft can serve as an interposition implant in the surgical treatment of trapeziometacarpal osteoarthritis. The main question this study aims to address is : \- Can interposition of a human umbilical cord amniotic membrane within the trapeziometacarpal joint reduces postoperative pain and improves thumb mobility, grip and pinch strength, and overall wrist function. Participant will: * Undergo surgical treatment of the trapeziometacarpal osteoarthritis with the interposition in articular joint of an amniotic membrane of umbilical cord allograft on Day 0 * Visit the center for a series of tests 1 month, 3 months, 6 months and 12 months after the surgical intervention.

Eligibility Criteria

Inclusion Criteria: * Patient presenting with symptomatic osteoarthritis of the trapeziometacarpal joint, with wrist pain ≥ 40/100 according to the PRWE pain subscale (scaled to 100). * Patient who has received medical treatment for functional symptoms for more than 3 months without improvement, and for whom surgical intervention is indicated. * Patient with radiographic stage I-II trapeziometacarpal joint osteoarthritis according to the Eaton-Glickel classification. * Patient able to understand, date, and sign the informed consent form. * Patient affiliated with a social security system or beneficiary of such a system. Exclusion Criteria: * Pregnant or breastfeeding woman ; woman without effective contraception. * Patient with scaphotrapeziotrapezoid (STT) joint osteoarthritis requiring prosthetic surgical treatment. * Patient with thumb osteoarthritis secondary to a systemic inflammatory disease (e.g., rheumatoid arthritis). * Patient with osteoarthritis experiencing an acute inflammatory flare, characterized by a warm, painful, and swollen joint at the time of enrollment. * Patient with amputated hand(s). * Patient presenting signs of neuropathy with functional impairment such as hyperesthesia. Neuropathy may be peripheral (nerve injury) or systemic (caused by diabetes or excessive alcohol consumption). * Patient lacking capacity to participate in rehabilitation or to comply with study follow-up. * Patient with a contraindication to anesthesia (poorly controlled epilepsy, neuropathy, etc.). * Person deprived of liberty by a judicial or administrative decision. * Adult subject under legal protection or unable to provide informed consent.

Contact & Investigator

Central Contact

Laurence BARNOUIN

✉ laurence.barnouin@tbf-lab.com

📞 4 72 68 69 09

Frequently Asked Questions

Who can join the NCT07435571 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Trapeziometacarpal Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07435571 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07435571 currently recruiting?

Yes, NCT07435571 is actively recruiting participants. Contact the research team at laurence.barnouin@tbf-lab.com for enrollment information.

Where is the NCT07435571 trial being conducted?

This trial is being conducted at Lyon, France, Lyon, France, Nantes, France, Saint-Jean-de-Védas, France.

Who is sponsoring the NCT07435571 clinical trial?

NCT07435571 is sponsored by TBF Genie Tissulaire. The trial plans to enroll 22 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology